Product Details
Giotrif
Afatinib20 mg
Tablet
DIN/PIN/NPN
02415666
Manufacturer
Boehringer-Ingelheim (Canada) Ltd./Ltee
Formulary Listing Date
2022-04-29
Unit Price
77.4784
Amount MOH Pays
77.4784
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01EB03
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Afatinib
Initial requests: For the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who meet the following criteria:
Dose: 40 mg orally once daily Exclusion Criteria:
Notes:
Renewal requests will be considered based on the following: Afatinib 40 mg once daily may be continued until evidence of disease progression or development of unacceptable toxicity at which point the drug should be discontinued. Patients should have their disease status assessed at least every two months. EAP Drug Request Form: |